EP0684764A4 - Treatment of androgen-associated baldness using antisense oligomers. - Google Patents

Treatment of androgen-associated baldness using antisense oligomers.

Info

Publication number
EP0684764A4
EP0684764A4 EP94909689A EP94909689A EP0684764A4 EP 0684764 A4 EP0684764 A4 EP 0684764A4 EP 94909689 A EP94909689 A EP 94909689A EP 94909689 A EP94909689 A EP 94909689A EP 0684764 A4 EP0684764 A4 EP 0684764A4
Authority
EP
European Patent Office
Prior art keywords
androgen
baldness
treatment
antisense oligomers
oligomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94909689A
Other languages
German (de)
French (fr)
Other versions
EP0684764A1 (en
Inventor
Mary Ellen Harper
Tod Mitchell Woolf
Lyle John Arnold Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Publication of EP0684764A1 publication Critical patent/EP0684764A1/en
Publication of EP0684764A4 publication Critical patent/EP0684764A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
    • C12Y103/99005—3-Oxo-5alpha-steroid 4-dehydrogenase (acceptor) (1.3.99.5), i.e. steroid-5alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treating androgen-associated hair loss, in particular decreasing the progression of male pattern baldness using nucleoside Oligomers and Oligomers useful in the described methods are provided.
EP94909689A 1993-02-19 1994-02-18 Treatment of androgen-associated baldness using antisense oligomers. Ceased EP0684764A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19543 1987-02-26
US1954393A 1993-02-19 1993-02-19
PCT/US1994/001748 WO1994018835A1 (en) 1993-02-19 1994-02-18 Treatment of androgen-associated baldness using antisense oligomers

Publications (2)

Publication Number Publication Date
EP0684764A1 EP0684764A1 (en) 1995-12-06
EP0684764A4 true EP0684764A4 (en) 1997-10-22

Family

ID=21793773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909689A Ceased EP0684764A4 (en) 1993-02-19 1994-02-18 Treatment of androgen-associated baldness using antisense oligomers.

Country Status (6)

Country Link
EP (1) EP0684764A4 (en)
JP (1) JPH08506961A (en)
AU (1) AU692148B2 (en)
CA (1) CA2156512C (en)
IL (1) IL108712A0 (en)
WO (1) WO1994018835A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739553B1 (en) 1995-10-06 1998-01-02 Oreal USE OF BRADYKININE ANTAGONISTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THE HAIR LOSS
WO1997038728A1 (en) * 1996-04-15 1997-10-23 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
US6489163B1 (en) * 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2003524586A (en) * 1998-05-21 2003-08-19 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for parenteral administration of oligonucleotides
JP2002515514A (en) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for local delivery of oligonucleotides
US20020086387A1 (en) * 2000-04-13 2002-07-04 Rachel Meyers 23155 novel protein human 5-alpha reductases and uses therefor
IT1318379B1 (en) * 2000-03-08 2003-08-25 Ira Srl COSMETIC OR PHARMACEUTICAL COMPOSITION USEFUL TO INHIBIT OR DELAY HUMAN ALOPECIA THROUGH TOPICAL APPLICATION OF THE COMPOSITION.
FR2832154B1 (en) * 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
WO2005042741A2 (en) * 2003-10-21 2005-05-12 Dyad Pharmaceutical Corporation METHODS AND COMPOSITIONS FOR TREATING 5alpha-REDUCTASE TYPE 1 AND TYPE 2 DEPENDENT CONDITIONS
DE102004025881A1 (en) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonucleotides for influencing hair growth
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
JP6768253B2 (en) * 2015-10-09 2020-10-14 井上　肇 How to get information about androgenetic alopecia in the subject
JP7407592B2 (en) * 2016-08-08 2024-01-04 オリパス コーポレーション Androgen receptor antisense oligonucleotide
JP7089511B2 (en) * 2016-10-11 2022-06-22 オリパス コーポレーション HIF1-α antisense oligonucleotide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
WO1994013326A1 (en) * 1992-12-08 1994-06-23 Genta Incorporated Formation of triple helix complexes using a novel motif

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
WO1994013326A1 (en) * 1992-12-08 1994-06-23 Genta Incorporated Formation of triple helix complexes using a novel motif

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9418835A1 *

Also Published As

Publication number Publication date
AU6243794A (en) 1994-09-14
IL108712A0 (en) 1994-05-30
EP0684764A1 (en) 1995-12-06
WO1994018835A1 (en) 1994-09-01
CA2156512A1 (en) 1994-09-01
JPH08506961A (en) 1996-07-30
CA2156512C (en) 2002-11-19
AU692148B2 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
EP0684764A4 (en) Treatment of androgen-associated baldness using antisense oligomers.
AU5531596A (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
ZA977513B (en) Skin tanning compositions and method.
GB2335147B (en) Methods and devices for inhibiting hair growth and related skin treatments
ZA93226B (en) Abrasive articles including a crosslinked siloxane, and methods of making and using same.
GB9506926D0 (en) Cystine-siicone copolymers and their use for treating keratin substrates
EP0718325A3 (en) Process for preparing ethylene-alpha-olefin-nonconjugated polyene random copolymer, copolymer obtained thereby, and uses of the copolymer
AU1645995A (en) Leather treatment process for leather coloring, leather coloring process performed on leather thereby treated, and leather article produced by the leather coloring process
EP0685219A3 (en) Hair treatment agent and process for its use.
AU7227394A (en) Method for surface treatment, means for carrying out the method and the use thereof
AU3124397A (en) Method and product for promoting hair growth and treating skin conditions
AU2836499A (en) Cosmetic method of treating skin
PL332579A1 (en) Application of 1-hydroxy-2-pyridinones in treating dermatological infections
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
PL313349A1 (en) Method of diagnoasing, progdnosticating and treating non-lymphatic tumours and their metastases
AU3488699A (en) Surface treatment process and system
AU6703394A (en) Method of treating depression using neurotrophins
GB9218763D0 (en) Hair and skin treatment method
GB9408480D0 (en) Treated natural or artificial hair for use in lengthening or thickening human hair, and methods, processes, apparatus and tools relating thereto
GB9820631D0 (en) Hair treatment composition, method and use
CA95615S (en) Tanned hide
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
AU6060199A (en) Method of treating hair loss using sulfonamides
PL337665A1 (en) (s) 2-methylamine-2-phenyl-n-butyl-3,4,5-trimethoxybezoate and application thereof in treating long-lasting pains
WO1998000129A3 (en) Anticonvulsant derivatives useful in treating psoriasis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950918

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/11

A4 Supplementary search report drawn up and despatched

Effective date: 19970903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20031218